Results 111 to 120 of about 22,968 (195)

Pseudo-senescence induced by palbociclib does not sensitise pleural mesothelioma cells to combinations with senolytics. [PDF]

Cell Death Dis
Sreeram I, Plans-Marin S, Cruz-Rodríguez M, Aliagas E, Palau-Gallinat D, Muñoz-Pinedo C, Nadal E.   +6 more
europepmc   +1 more source

Real-world progression-free survival 2 (PFS2) and tumor response of CDK4/6 inhibitors plus an aromatase inhibitor in patients with HR+/HER2- metastatic breast cancer in US routine clinical practice. [PDF]

Breast
Rugo HS, Brufsky A, Layman RM, Liu X, Li B, McRoy L, Cohen AB, Estevez M, Lynce F, Cottu P, Thill M, Curigliano G.   +11 more
europepmc   +1 more source

Impact of Comorbidities on Clinical Outcomes and Quality of Life of Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer Treated With Palbociclib in the POLARIS Study. [PDF]

Cancer Med
Tripathy D, Blum JL, Karuturi MS, McCune S, Kurian S, Moezi MM, Anderson DM, Ji Y, Pluard TJ, Migas J, Lakhanpal S, Jepsen E, Wang Y, Montelongo MZ, Zhang Z, Cappelleri JC, Gauthier E, Rocque GB.   +17 more
europepmc   +1 more source

A Rare Case of Palbociclib-Induced Pancolitis: Clinical Insights and Literature Review. [PDF]

Cureus
Bidani K, Chouthai AA, Broder A, Velpari S.   +3 more
europepmc   +1 more source

Functional annotation of ESR1 gene fusions in estrogen receptor-positive breast cancer [PDF]

, 2018
Crowder, Robert, Davies, Sherri R, et al,, Hoog, Jeremy, Iglesia, Michael, Li, Shunqiang, Ma, Cynthia X, Maher, Christopher A, Phommaly, Chanpheng, Rogers, Anna, Shao, Jieya, Watson, Mark A, Zhang, Jin   +12 more
core   +1 more source

Overall survival from the open-label phase II trial of palbociclib in patients with advanced well-differentiated/dedifferentiated liposarcoma. [PDF]

ESMO Open
Babatunde OO, Seier K, Schwartz G, Keohan ML, D'Angelo SP, Gounder MM, Chi P, Antonescu CR, Landa J, Qin LX, Crago AM, Singer S, Koff A, Tap WD, Dickson MA.   +14 more
europepmc   +1 more source

Missingness in Eligibility Criteria for Target Trial Emulation in EHR With Survival Outcomes. [PDF]

Stat Med
Shen J, Linn KA, Clark AS, Mamtani R, Hubbard RA.   +4 more
europepmc   +1 more source

HES1 oscillations are required for cell cycle reentry in oestrogen receptor-positive breast cancer cells. [PDF]

Proc Natl Acad Sci U S A
Cottrell O, Rowntree A, Chopra K, Mackellar E, Noble B, Dixon HL, Healy C, Clarke RB, Papalopulu N.   +8 more
europepmc   +1 more source

Real-world effectiveness of palbociclib in combination with an aromatase inhibitor in HR+/HER2- bone-only metastatic breast cancer. [PDF]

Breast
Brufsky A, Layman RM, Liu X, Li B, McRoy L, Cohen AB, Estevez M, Cottu P, Curigliano G, Rugo HS.   +9 more
europepmc   +1 more source

Osteosarcoma 3D patient derived cultures to test genome-informed personalized treatment options: a feasibility study. [PDF]

Front Med (Lausanne)
Palubeckaitė I, Venneker S, Franceschini N, Wijers-Koster P, Agaser C, Briaire-de Bruijn I, Kruisselbrink AB, van den Akker B, Mei H, Cleton-Jansen AM, Gelderblom H, van de Sande MAJ, Bovée JVMG.   +12 more
europepmc   +1 more source